Antleron
Develops end-to-end digital factories for personalized biomanufacturing, integrating 3D printing, bioreactors, and AI-driven process control.
- CEO / Founder
- Jan Schrooten
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- $2.2M
- Latest Round
- Grant
- Key Investors
- EIT Health, QbD Group, myNEO, VUB
Technology & Products
Key Products
CellGuide®; NEXUS; Bioprinting workflows
Technological Advantage
Hybrid approach combining hardware (bioprinting/bioreactors) with digital twins for predictive process optimization, reducing the gap between lab-scale and clinical-scale production.
Differentiation
Value Proposition
Enables 'living therapy factories' by integrating bioprinting with automated bioreactors and digital twins to optimize and scale personalized medical treatments.
How They Differentiate
Focuses on the 'Platform' level, integrating 3D Systems' hardware with proprietary bioreactor technology and digital twin software for a complete biomanufacturing workflow.
Market & Competition
Target Customers
Innovators in advanced therapies, gene/cell therapy developers.
Industry Verticals
Medical; Regenerative Medicine; Biotechnology
Competitors
Cellink (BICO); Aspect Biosystems; Organovo
Growth & Milestones
Growth Metrics
Team of ~25+ employees as of 2025; Lead technical partner for the AstroCardia project (heart-on-a-chip research on the International Space Station); Received Crédit d'Impôt Recherche accreditation by French Ministry (Nov 2025); Third Trends Gazellen nomination (Jan 2025).
Major Milestones
Founded in 2014; Announced 3D Systems partnership in 2018; Developed 'living therapy factory' workflows; Received Crédit d'Impôt Recherche accreditation by French Ministry (Nov 2025); Third Trends Gazellen nomination (Jan 2025); Antleron & Novasign digital twin showcased at ESACT 2024.
Notable Customers
3D Systems; Scilife; VIVOLTA; SCK CEN; Space Applications Services